AxoGen, Inc. logo

AxoGen, Inc.

AXGN

NASDAQHealthcareMedical - Devices

Latest quote

$50.36

+$3.96 · +8.53%

Aug 21, 3:55 PM ET

AXGN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

73

Undervalued

Momentum

74

Gaining

Sentiment

63

Bullish

Risk resilience

56

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Michael D. Dale
Listed since
Dec 17, 1986
Employees
622

Market position

Volume
1.78M
1.48× average
Average volume
1.21M
Average daily volume
Market cap
2.71B USD
Beta
1.14
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.54B USD
EV / EBITDA
8,017.22×
Earnings yield
-1.04%
Free cash flow yield
-0.19%

Profitability & efficiency

Return on equity
-12.19%
Return on assets
-7.08%
Return on invested capital
-3.91%

Financial health

Current ratio
5.11×
Altman Z-score
33.2
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends92%51%10%-32%Gross margin, FY2021: 81.99%Gross margin, FY2022: 78.51%Gross margin, FY2023: 76.64%Gross margin, FY2024: 75.79%Gross margin, FY2025: 74.31%Operating margin, FY2021: -19.96%Operating margin, FY2022: -21.44%Operating margin, FY2023: -13.50%Operating margin, FY2024: -1.75%Operating margin, FY2025: -3.49%Net margin, FY2021: -21.19%Net margin, FY2022: -20.89%Net margin, FY2023: -13.66%Net margin, FY2024: -5.32%Net margin, FY2025: -6.97%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 81.99%. Gross margin FY2022 78.51%. Gross margin FY2023 76.64%. Gross margin FY2024 75.79%. Gross margin FY2025 74.31%. Operating margin FY2021 -19.96%. Operating margin FY2022 -21.44%. Operating margin FY2023 -13.50%. Operating margin FY2024 -1.75%. Operating margin FY2025 -3.49%. Net margin FY2021 -21.19%. Net margin FY2022 -20.89%. Net margin FY2023 -13.66%. Net margin FY2024 -5.32%. Net margin FY2025 -6.97%.

Income trends

Revenue

225.21M USD+20.21%

Operating income

−7.85M USD-138.79%

Net income

−15.7M USD-57.60%
Income trends across reported periods250.7M USD148.73M USD46.77M USD−55.2M USDRevenue, FY2021: 127.36M USDRevenue, FY2022: 138.58M USDRevenue, FY2023: 159.01M USDRevenue, FY2024: 187.34M USDRevenue, FY2025: 225.21M USDOperating income, FY2021: −25.42M USDOperating income, FY2022: −29.71M USDOperating income, FY2023: −21.46M USDOperating income, FY2024: −3.29M USDOperating income, FY2025: −7.85M USDNet income, FY2021: −26.99M USDNet income, FY2022: −28.95M USDNet income, FY2023: −21.72M USDNet income, FY2024: −9.96M USDNet income, FY2025: −15.7M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 127.36M USD. Revenue FY2022 138.58M USD. Revenue FY2023 159.01M USD. Revenue FY2024 187.34M USD. Revenue FY2025 225.21M USD. Operating income FY2021 −25.42M USD. Operating income FY2022 −29.71M USD. Operating income FY2023 −21.46M USD. Operating income FY2024 −3.29M USD. Operating income FY2025 −7.85M USD. Net income FY2021 −26.99M USD. Net income FY2022 −28.95M USD. Net income FY2023 −21.72M USD. Net income FY2024 −9.96M USD. Net income FY2025 −15.7M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue225.21M USD187.34M USD159.01M USD138.58M USD127.36M USD
Cost of goods sold57.86M USD45.36M USD37.14M USD29.78M USD22.93M USD
Gross profit167.35M USD141.98M USD121.87M USD108.81M USD104.43M USD
Research and development32.89M USD27.77M USD27.34M USD25.63M USD24.18M USD
Selling, general, and administrative142.32M USD117.5M USD115.99M USD112.89M USD105.67M USD
Operating expenses175.2M USD145.26M USD143.33M USD138.52M USD129.84M USD
Interest expense7.7M USD8.21M USD2.84M USD624K USD1.36M USD
Depreciation and amortization8.19M USD7.84M USD5.55M USD4.85M USD4.74M USD
Operating income−7.85M USD−3.29M USD−21.46M USD−29.71M USD−25.42M USD
Net income−15.7M USD−9.96M USD−21.72M USD−28.95M USD−26.99M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+128.12%
11 comparable reports
Latest EPS result
0.12
Estimate 0.12 · Miss by 1.15%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.180.10.02-0.06Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 0.08, estimate 0.04, surprise +100.00%, Beat. Q2 2025, reported May 8, 2025: actual -0.02, estimate -0.01, surprise -100.00%, Miss. Q3 2025, reported Aug 5, 2025: actual 0.12, estimate 0.06, surprise +100.00%, Beat. Q4 2025, reported Oct 29, 2025: actual 0.12, estimate 0.09, surprise +33.33%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.07, estimate 0.089, surprise -21.16%, Miss. Q2 2026, reported Apr 28, 2026: actual 0.07, estimate 0.12, surprise -41.67%, Miss. Q3 2026, reported Jul 29, 2026: actual 0.12, estimate 0.121, surprise -1.15%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.14, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates76.12M65.87M55.61M45.35MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 49.41M USD, estimate 48.28M USD, surprise +2.33%, Beat. Q2 2025, reported May 8, 2025: actual 48.56M USD, estimate 53.34M USD, surprise -8.97%, Miss. Q3 2025, reported Aug 5, 2025: actual 56.66M USD, estimate 56.89M USD, surprise -0.40%, Miss. Q4 2025, reported Oct 29, 2025: actual 60.08M USD, estimate 59.9M USD, surprise +0.30%, Beat. Q1 2026, reported Feb 24, 2026: actual 59.9M USD, estimate 59.03M USD, surprise +1.48%, Beat. Q2 2026, reported Apr 28, 2026: actual 61.46M USD, estimate 57.85M USD, surprise +6.24%, Beat. Q3 2026, reported Jul 29, 2026: actual 69.73M USD, estimate 67.1M USD, surprise +3.92%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 73.2M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$52.20

3.57% upside
Past 12 months12-month forecastHigh $55.00Average $52.20Low $48.00

Rating distribution

19 ratings
Strong buy00%
Buy1684%
Hold316%
Sell00%
Strong sell00%

Recent analyst actions

10 institutions
Wells FargomaintainOverweight
JefferiesmaintainBuy
Raymond JamesmaintainOutperform

AXGN news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$1.00

2010 complete year+2296.8% since 1992

Corporate action history

Dividend

Ex-dividend Jan 27, 2010

$1.00

Special

Record Jan 29, 2010 · Payment Feb 12, 2010

Dividend

Ex-dividend Feb 23, 2005

$0.06

Special

Dividend

Ex-dividend Jul 10, 1992

$0.0417

Special

AXGN peers

Continue in GoAI

Research AXGN

research.disclaimer